Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2870818 | 0.90 | DRD2 (0.53) | DRD2CACNA1HTDP1MEN1GAA | |
| SCHEMBL31301242 | 0.84 | DRD2 (0.63) | DRD2CACNA1HTDP1MEN1GAA | |
| SCHEMBL28210559 | 0.83 | DRD2 (0.52) | DRD2CACNA1HTDP1MEN1GAA | |
| SCHEMBL24172673 | 0.81 | DRD2 (0.56) | DRD2CACNA1HTDP1MEN1GAA | |
| SCHEMBL31301250 | 0.81 | DRD2 (0.56) | DRD2CACNA1HTDP1MEN1GAA | |
| SCHEMBL4024516 | 0.81 | DRD2 (0.56) | DRD2CACNA1HTDP1MEN1GAA | |
| SCHEMBL29290724 | 0.81 | DRD2 (0.56) | DRD2CACNA1HTDP1MEN1GAA | |
| SCHEMBL485945 | 0.80 | DRD2 (0.55) | DRD2CACNA1HTDP1MEN1KMT2A | |
| SCHEMBL7220892 | 0.80 | DRD2 (0.55) | DRD2CACNA1HTDP1MEN1KMT2A | |
| SCHEMBL13202614 | 0.80 | DRD2 (0.59) | DRD2CACNA1HTDP1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092901-B1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | SENHWA BIOSCIENCES INC (TW) | 2020-04-29 | — | — | EP | disclosed |
| EP-3092901-B1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | SENHWA BIOSCIENCES INC (TW) | 2020-04-29 | — | — | EP | disclosed |
| EP-3092901-A1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | Senhwa Biosciences, Inc. (TW) | 2016-11-16 | — | — | EP | disclosed |
| EP-3092901-A1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | Senhwa Biosciences, Inc. (TW) | 2016-11-16 | — | — | EP | disclosed |
| EP-2214491-B1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | SENHWA BIOSCIENCES INC (TW) | 2016-07-13 | — | — | EP | disclosed |
| EP-2214491-B1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | SENHWA BIOSCIENCES INC (TW) | 2016-07-13 | — | — | EP | disclosed |
| US-9238657-B2 | Cephalosporin having catechol group | SHIONOGI & CO., LTD. (JP) | 2016-01-19 | — | — | US | disclosed |
| EP-2341053-B1 | CEPHALOSPORIN HAVING CATECHOL GROUP | SHIONOGI & CO (JP) | 2016-01-13 | — | — | EP | disclosed |
| US-8853234-B2 | Quinolone analogs and methods related thereto | SENHWA BIOSCIENCES, INC. (TW) | 2014-10-07 | — | — | US | disclosed |
| US-8853234-B2 | Quinolone analogs and methods related thereto | SENHWA BIOSCIENCES, INC. (TW) | 2014-10-07 | — | — | US | disclosed |
| EP-2341053-A1 | CEPHALOSPORIN HAVING CATECHOL GROUP | Shionogi & Co., Ltd. (JP) | 2011-07-06 | — | — | EP | disclosed |
| US-7928100-B2 | Quinolone analogs and methods related thereto | CYLENE PHARMACEUTICALS, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928100-B2 | Quinolone analogs and methods related thereto | CYLENE PHARMACEUTICALS, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928100-B2 | Quinolone analogs and methods related thereto | CYLENE PHARMACEUTICALS, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2214491-A1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | Cylene Pharmaceuticals, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| US-20090093455-A1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-09 | — | — | US | disclosed |
| US-20090093455-A1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-09 | — | — | US | disclosed |
| WO-2009046383-A1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009046383-A1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | CYLENE PHARMACEUTICALS, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
| US-20090093455-A1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | SENHWA BIOSCIENCES, INC. (TW) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093455-A1 | QUINOLONE ANALOGS AND METHODS RELATED THERETO | BAX, NQO2, BAD | DRD2 4553/4885CACNA1H 4378/4885TDP1 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.